002755.SZ
奥赛康
SZSE · Healthcare · C 制造业 · CN
CNY 11.97
−7.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 1.8B | 1.8B | 1.4B | 1.9B |
| Cost of Revenue | 339.5M | 351.9M | 331.6M | 277.1M | 243.6M |
| Gross Profit | 1.4B | 1.4B | 1.4B | 1.2B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 125.8M | 158.6M | 177.3M | 472.0M | 588.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 132.4M | 133.0M | 134.5M | 133.0M | 139.6M |
| Selling & Marketing Expense | 872.3M | 914.5M | 1.0B | 840.2M | 1.2B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.1B | 1.2B | 1.3B | 1.5B | 1.9B |
| Cost and Expenses | 1.5B | 1.6B | 1.7B | 1.7B | 2.2B |
| Operating Income (EBIT) | 315.0M | 254.8M | 156.9M | (219.9M) | (260.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 314.1M | 253.1M | 151.5M | (200.9M) | (262.5M) |
| Income Tax Expense | 47.6M | 39.4M | 23.0M | 6.6M | 3.7M |
| Bottom Line | |||||
| Net Income | 266.3M | 236.6M | 160.3M | (148.5M) | (225.8M) |
| Earnings from Cont. Ops | 266.6M | 213.7M | 128.5M | (207.5M) | (266.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 266.3M | 236.6M | 160.3M | (148.5M) | (225.8M) |
| Per Share | |||||
| Basic EPS | CN¥0.28 | CN¥0.25 | CN¥0.17 | (CN¥0.16) | (CN¥0.24) |
| Diluted EPS | CN¥0.28 | CN¥0.25 | CN¥0.17 | (CN¥0.16) | (CN¥0.24) |
| Revenue Per Share | CN¥1.87 | CN¥1.88 | CN¥1.89 | CN¥1.55 | CN¥1.99 |
| Shares | |||||
| Basic Shares Outstanding | 938.5M | 946.4M | 942.9M | 928.3M | 940.9M |
| Diluted Shares Outstanding | 938.5M | 946.4M | 942.9M | 928.3M | 940.9M |
| Profitability Metrics | |||||
| EBITDA | — | 385.9M | 246.0M | (133.3M) | (165.2M) |
| D&A | — | 131.1M | 89.1M | 86.5M | 94.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026